Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I would encourage Soma to create a Daxi Ad some like this: (send the ad to your email list, put on Instagram and Facebook)
Attention all Botox/Dysport patients! If you would like to get longer duration, quicker onset and more beautiful skin tone, Daxxify is now available for the SAME PRICE as Botox or Dysport!
Daxi will give you longer duration, quicker onset and better skin tone. Our office will guarantee the longer Daxi Duration!!
Call now and Receive $25 off your first treatment. We provide a written guarantee for longer duration with Daxi!
Require a 2 week follow up to check the patient and build a better relationship!
If a patient returns with a duration issue, the Revance rep will provide complimentary Daxi
Patient must tell you how many Botox units they received which will go i their chat! Then inject them with double the Daxi units!
You will have many new patients for $25 per patient! Average patient spends $538 per visit!
The magic of Daxi will be when patients begin to tell their friends that they should go to “their” doctor and get Daxi. Practices need to advertise their price for Daxi so patients know where to go!
Once 1 big injector in an area begins advertising their Daxi price, every other injector will be force to offer Daxi or risk losing patients! Patients who purchase Daxi at the same price as Botox will never return to Botox!
Price and value are the #1 priority of every patient!
Dew, this is not your first rodeo!
What are your thoughts on what will happen with RVNC management over the next month or 2?
and the RVNC stock price?
At the current pace, the stock will hit zero
by next Friday.
Copied the below statement from another message board.. so accurate!!!!
$RVNC There will be Business College Case Studies done on the launch of Daxxify. It’s still in motion but the first few chapters will be how to do everything wrong. We’ll see what the last few chapters look like. There is a valuable product there. But how much $$ and resources will need to be exhausted to get there is the question.
Great Business Case Study on How to Kill a GREAT Product with a terrible marketing/pricing strategy and how to kill investor confidence!
Wonder how Teoxane is feeling about being down $50 million in 30 days in the Mark Foley pit?
Teoxane needs to take charge and bring RVNC out of the mess Foley has created.
Another Foley bad decision is the packaging of Daxi. Should be in a 200 unit vial, not a 100 unit vial so it is easy for the injector to use and calculate!
This could be quickly resolved by offering a 200 unit vial of Daxi. Allergan sells both a 50 unit and a 100 unit vial of Botox.
Dysport figured this out as Dysport comes in a 300 unit vial.
Another example of a bad Foley decision!
From Modern Aesthetics
COO
Ms. Jordan joined Revance earlier this year as Senior Vice President of Commercial.
Revance Taps Erica Jordan as COO image
Erica Jordan is now Revance Therapeutics, Inc.’s Chief Commercial Officer (CCO), Aesthetics.
“Given the importance of the DAXXIFY launch, I’m excited to elevate Erica to the position of Chief Commercial Officer, Aesthetics reporting directly to me. Having worked closely with Erica over the past several months, I have tremendous confidence in her abilities and leadership skills, and she’s been an invaluable partner as we’ve evolved our strategy based on customer feedback. In this role, Erica will not only help us drive the desired DAXXIFY adoption but also help ensure that we continue to grow our RHA filler business and begin to realize the synergies of our portfolio,” says Mark J. Foley, Chief Executive Officer of Revance, in a news release. “Erica joined us earlier this year and has a demonstrated track record as a global healthcare leader driving commercial transformation and growth, sales and marketing excellence, flagship product launches and operational efficiencies. Her extensive experience and strong ability to build partnerships both internally and externally, will be invaluable as we seek to maximize the market opportunity of our innovative products.”
“I’ve seen first-hand the tremendous excitement and potential that our product portfolio offers to the aesthetics market,” says Ms. Jordan. “With key launch initiatives underway, I look forward to working with Mark and the rest of the team to continue to elevate Revance and its portfolio of products in the aesthetics marketplace. We will build on our progress, leverage learnings and partner with our current customers to continue to establish the value of DAXXIFY.”
Ms. Jordan joined Revance earlier this year as Senior Vice President of Commercial. Prior to joining Revance, she served as President of the Metrex division at Envista Holdings. There, she also held the role of Senior Vice President, Sales & Marketing for the Ormco division. Before Envista Holdings, Ms. Jordan served as Vice President, Global Marketing for Change Healthcare where she developed and executed the commercial strategy for the first-ever cloud-based radiology enterprise imaging platform. She has held several marketing, commercial and operational leadership roles at Phillips Healthcare, including her role as Vice President, Senior General Manager. In addition, she held senior leadership roles at Fujifilm Medical Systems, Siemens Medical Solutions and GE Healthcare.
Ms. Jordan received her B.S. in Marketing and Finance from the University of Wisconsin-Milwaukee and is an active member of the Women Business Leaders of the US Health Care Industry Foundation.
Dew, agree Foley brought Zeltiq to a profitable state and sold it to Allergan who significantly over paid. Coolsculpting is a dog product and barely does $300 million total sales per year. Coolsculpting continues to cut head count as sales decline. There was no competitor and the technology was new, which is a very different market from Daxi and the mature toxin market!
Foley has been on an ego trip and now after making a half dozen mistakes in 18 months the stock is being crushed. Foley is way over his head in the toxin market which is why he keeps saying “I don’t know “…the guy is clueless!
Revance will become profitable and probably be bought! Foley does not know what he is doing and does not deserve to try to lead the company when he is figuring it out as he goes. There are leaders out there who know this market and can get Revance to the finish line in half the time it will take Foley.
The sales team has been telling management to make the price change for many months and they were afraid each time they brought it up that they would get fired for disagreeing with the ego management! This is not the culture of a good leader!
Lilly just got FDA approval for their version of Ozempric. Zepbound!!!
They start shipping in two weeks, not 10 months like Revance with CD Daxi.
This is how’s it’s supposed to work when you get FDA approved.
Yes!!!
1. Create a Social Media message/communication which educates patients on the benefits of Daxi.
2. Create an App which provides a Patient Loyalty Program to communicate with patients for loyalty, promotion, education, pricing, etc!
3. Stop waisting money on non essential expenses—tight cost control!
4. Reward practices for advertising their price of Daxi
5. Create a Daxi Day on a National Level
6. Have the reps encourage practices to create special Daxi Day events every other month and reward each patient with a small amount of free product supported by the rep!
7 Get doctors on TV talking about Daxi!
8 promoted BillBoard advertising of Daxi
9 Encourage Practices to create their own Daxi Dilution which is a lower strength for less money and also offer Standard Daxi which is double the units. This gives patients 2 price points. Price is the magic!
10 price standard Daxi Double equal to Botox. This is now the Revance recommendation!
Just do what Allergan, Galderma, Merz and Evolus are doing! Daxi is a better product and at the same price will win over the patient every time! Same price for a better product!!
Just a few for you :)
Foley must have screwed over a few money managers on WS and they definitely want him fired! Foley is a cancer and the Board of Directors need to remove him ASAP!
No one has faith in Foley..bad leadership!
RVNC will soon be valued less than Evolus. Foley needs to go!!!
Revance just published that Deloitte awarded Revance the Deloitte Technology Fast 500 for innovation and fast growing companies.....If RVNC had good leadership this company would be #1 on the list....too bad we can not trade Mark Foley for David Moatazedi from Evolus. David is an excellent leader and would have RVNC doing amazing. Then Foley would quickly drive Evolus into bankruptcy with his bad decisions and leadership!
RVNC: Excellent products with Bad Leadership
EOLS: Average to below Average product with Amazing Leadership
Poor management is the top threat facing companies, according to Warren Buffett!...
Hello RVNC!
Here is a list of a few Bad Foley Decisions:
-Hired Daxi sales team with no Daxi approval -waisted millions
-Plantar Fasciitis study - waisted millions
-CRL …Foley did not know- waisted millions
-Premium Price Strategy - killed sales and cost millions
-No Advertising of Daxi Price- cost millions
-18th Floor Buildout—- waisted millions
-No Daxi Marketing—-cost millions
-Daxi approved for cosmetic—start selling 4 months later—-waisted millions
-Daxi approved for CD - start selling 10 months later—-waisted millions.
These are just a few of the Foley bad decisions! This guy is killing RVNC! Maybe someone should check if Foley is aware that Daxi was approved for CD…Foley always says he did not know what was happening!
Just to give some color, Dustin was in charge of giving tours of the 18th floor at the past Revance sales meeting which Foley spent millions finishing the EMPTY 18th floor! The 17th floor is also half empty ! The sales team was very disappointed that Foley would spend millions on an empty floor and Revance has NO Daxi MARKETING Team or programs ..the sales team was confused as to the bad allocation of money and poor support!
When will the investors or the Board of Directors kick Foley out? This guy has no idea what he is doing and is killing the Time Magazine Product of the Year!
And the sales team has been telling Foley that injectors will not buy Daxi because the price is too high for the last 6 months…Foley knew all this and refused to lower the price until Daxi sales tanked! 100% Foley to blame!
I believe the Jeaveau double dose results provide UP TO 6 months duration! They never published the average duration of their double dose because it is low!
Daxi is 6 to 9 months duration with the average patient getting 6 months.
My guess is the Average Jeaveau double dose patient got 4 to 41/2 months of duration
which is similar to a double Botox duration!
Very different from Daxi and a play on words from Jeaveau!
This article in Modern Aesthetics was written back in January 2023 prior to the lowering of the Daxi price to injectors on September 1, 2023. Revance is recommending injectors price Daxi at the same price as Botox and Revance is now allowing practices to advertise their price for Daxi on social media. So an informed Daxi patient can now get a 6 month duration Daxi treatment for the same price as Botox!
Aesthetic Patients budget a specific amount of dollars for their treatments so this will result in more Daxi patients also getting filler at the same appointment! A win for both the injector and the patient!
Foley told the sales team at their meeting in Nashville about a month ago, that RVNC has plenty of cash and they have nothing to be concerned with! There are VC companies who are shorting the RVNC stock and driving it down. It will take a few months for the stock to recover.
With Daxi now costing practices the same as Botox, the goal is for injectors to price Daxi at the same price as Botox to the patient. This strategy is now winning and both patients and injectors are loving Daxi!
Per Q3 sales forecast, I support Dew’s numbers! The sales team did not hit their Q3 target revenue as a whole which is typically higher than WS forecast. Many of the sales reps did hit their numbers, but others did not! Q4 sales are going very well, but its is hard to determine if it is the quarter or if the lower price is driving sales.
Most likely an Earnings Leak..
If you check Instagram for Daxi reviews, there are now hundreds of injectors and patients who are beyond thrilled with their Daxi treatment…24 hours onset, double the duration of Botox and amazing skin tone all for the SAME PRICE as 20 yr old Botox which continues to lose market share each quarter! The Botox market share loss is normal for a 20 year old product going through the normal life cycle!
Was discussing the many RVNC shorts with an attorney on Wall Street and he would not be surprised if Abbive was behind many of the shorts! He feels Abbive is desperate and Botox is similar to Humaria but Abbive has no solution to replace the lost Botox Revenue…will be a slow death to Botox an out of date product!
Mark Foley Train Wreck…Foley has killed Revance with his lack of leadership and terrible expenditures decisions! Bad decision after decision! Foley has created a sinking ship with an Award Winning Product! Great product and terrible Foley Leadership! Foley needs to go!!!! Expenses are growing faster than revenues…RVNC needs to cut spending and grow sales.
Foley spent millions and millions on the 18th floor ( which is totally empty) and has no Daxi Marketing Team! What a joke!
Other aesthetic Presidents laugh at Foley! They would never hire him!
The new lower Daxi Pricing was communicated to the RVNC sales team on September 1st and there was also a special monetary promotion offered to the sales team for September around higher Daxi sales dollars. So the reps were incentivized to sell higher quantities of Daxi.
Spoke to an injector earlier this week who was a big Botox user. She has now injected over 500 patients with Daxi and her patients are charged the same price for Botox or Daxi. Same price to the patient for 40 units of Botox/80 units of Daxi or 50 units of Botox /100 units of Daxi, etc….same price for both.
It took this very experienced injector 4 months to perfect her Daxi injections. The frontalis now gets a 2cc Daxi dilution ( to create more spread) and the galbellar and crows feet get a 1 cc Daxi dilution. She has both dilutions pre-drawn in B&D syringes in separate trays to create more efficiency in the patient room.
Her words, “Every patient now chooses Daxi over Botox due to the 24 hrs onset, longer duration of action and the peptide is icing on the cake creating the beautiful skin tone.”
She believes the majority of injectors in the USA are still working through this learning curve and once a patient is injected with Daxi, the patient will never return to Botox.
According to other conversations, Q4 Daxi and RHA sales are both selling very well.
Daxiffy onset is 24 hrs, duration is 2 months more or double Botox and the peptide gives the skin an amazing glow! Now costing injectors the same price as Botox, Daxi should be priced the same price as Botox to the patient.
Why choose a 20 yr old product (Botox) when you can buy a NEW PRODUCT ( Daxxify) with better features and functionality for the same price!!
If injectors are pricing Daxi higher, they are just being greedy and with the new policy to allow price advertising, patients will switch to lower priced injectors! Patients are all about price!!! Education of Patients is the Magic!!
Thank you Time Magazine for your unbiased honesty!
I still feel Mark Foley needs to be kicked out due to the MANY BAD DECISIONS he has made! The guy is a mess!!!
RVNCfan is most likely a friend of CosmeticMD and they both have monetary or person motivation to spread false information!
I would not be surprised if RVNC begins shipping therapeutic CD vials in the next 2 months, Nov or Dec . …In all honestly, many of these therapeutic doctors have already gone through the Daxi CD learning curve and will be the training doctors on the RVNC Zoom calls for their colleagues!
The therapeutic price approval of Daxi should be quick as the Daxi is priced the same or lower than other toxins and provides longer duration for the patient!
Revance has a Medical Science Consultant for each region in the USA. The MSC can discuss any and all off label applications…the sales rep can not give off label recommendations.
Looks like the big Investment Fund Managers have decided to take their RVNC profits back from the Venture Capital Managers who have been stealing their money and making them look bad with all the VC Shorts!
About time Investment Fund Managers !!!
Recommend you go the “Injectors.lounge” on Instagram and read all the comments on “how has Daxxy worked for you so far”. This will give you a good overview of the thoughts and opinions of a wide range of injectors.
It is very apparent that Dustin and Daxi Marketing team have created a major mess of the Daxi Launch!
The goal of Cosmetic Daxi is to capture 30% market share! This is 100% achievable!
RVNC has additional work to do on their cosmetic pricing strategy and Daxi marketing message! Injectors have not been updated with the new pricing! Injectors are also confused about dilution and the active ingredient. In the worst case, patients are getting the same duration as Dysport. Dysport lasts a little longer than Botox since Dysport has slightly more active ingredient. Some Daxi patients (40% to 50%) are getting 4 to 5 months duration.
Daxi should cost the patient the same amount as Dysport or Botox. Pricing Daxi equal to Dysport /Botox will give 40% to 50% of the patients longer duration than Dysport/Botox. This is an incentive for patients to switch and injectors to have the conversation. Daxi onset is 24 hrs which is loved by all.
For therapeutic, CD patients will most likely see an additional 4 to 6 weeks duration over Botox which will make Daxi adoption very successful! The lower adverse events, quick onset and longer duration of Daxi will be a major advantage over Botox.
RVNC Board of Directors are clueless! They are responsible for this mess!
RVNC is now valued less than HydraFacial. Just shows how bad RVNC leadership is both Foley and the Board of Directors!
Foley needs to put on big boy pants make an announcement and stop the uncertainty! Uncertainty on Wall Street means sell!
Foley needs start making good decisions! Like stop the CD PreView program, create a marketing campaign and start selling Therapeutic vials.
Taryn Conway was announced at the sales meeting last week as missing due to personal issues. She was a bully to the sales team and had no idea what the cosmetic industry was all about. She came from Allergan Eye Care. If she has resigned, this is another great step!
Per conversations, the sales team is so happy and excited that Foley is now in charge! Dustin and Taryn had too much control and made many bad decisions!
Was confirmed that advertising price is allowed.
IMHO- Aesthetic Practices can now ADVERTISE DAXI PRICE on Instagram, Facebook and other social media platforms…THANK RVNC Board of Directors!!!
This is a huge step forward to educate patients about Daxi.marketing impressions are extremely important!!!!
IMHO - the RVNC Marketing team decreased the price of Daxi so practices can purchase Daxi at the same cost as Botox. Any way a practice dilutions Daxi ( 1 unit of Daxi to 1 unit of Botox…Daxi will give 3 weeks more duration than Botox and onset is 24 hrs, 1.5 units of Daxi to 1 unit of Botox..Daxi will give 6 weeks more duration than Botox and onset is 24 hours and 2 units of Daxi to 1 unit of Botox..Daxi will give double the duration of Botox and 24 hour onset).
The goal is for every practice to price Daxi at
the same total price to the patient as Botox. Any way the practice dilutes Daxi, the patient will get a better outcome!
If the practice is charging $12 per unit for Botox and the typical patient receives 40 units = $480. If this patient gets Daxi 2, then they would be charged $6 per unit for Daxi since they are get 2 times the units of Daxi vs Botox.
The cost to the practice is the same for
Daxi 2 vs Botox.
If the practice does a 1.5 dilution of Daxi and charges the patient $480, the practice makes more money vs. Botox and the patient gets longer duration than Botox.
My opinion, the 1.5 dilution is the sweet spot which practices will migrate to as the practice makes more profit and the patient gets longer duration than Botox.
RVNC does not have an indication for Daxi Lite so the MSL must disclose this with injectors.
IMHO - sales of Daxi have increased with the decrease in price. Typically, Q4 is a very strong quarter for toxins and fillers due to the holidays.
RVNC Management seems to have little or no concern with the stock price drop and the shorts continue driving the price down. For example, yesterday, on just Fintel there were almost 500,000 short shares traded. I am sure the large fund investors are having discussions with Foley. As we can see, large investors are staying in…why?
RVNC had a sales meeting in Nashville this week with the entire sales team. They rolled out new/updated marketing/branding materials and everything is looking good.
IMHO - Q3 sales came in strong as many big MedSpas are moving ahead with Daxi/RHA do to higher profit margins with these products versus Botox/Juvederm.
The lower dispersion concern of Daxi is easily resolved with additional injection points/closer to each other which is what is recommended by Daxi trainers around the USA.
I hope and pray the Board of Directors at RVNC are reading these posts. They need to fix these issues!!! Daxi is an AMAZING product!!!
Injectors are being front loaded with diagrams and unit recommendations for the frontalis prior to injecting patients with Daxi. Injector Trainers from all over the USA are all over this with diagrams and unit recommendations. The frontalis is not an issue!
RVNC Management was ignoring the big MedSpas who are becoming the top users of Daxi. Switching from Botox to Daxi adds 10% net profit to their bottom line which is HUGE! And typically, Toxin Revenue is 50% of the Med Spa's total sales revenue...so a MedSpa doing $20 million in total sales revenue will do $10 million in Toxin sales revenue. 10% additional net profit on $10 million is $1 million more in the owners pocket...this is HUGE! No additional work, cost or expenses...Just $1 million additional profit. HELLO!!!!
Once a patient switches to Daxi from Botox they will never go back to Botox. Imagine, if you could buy the Lexus LS for less then the Ford Tarsus...that is what is now happening with Daxi ( 24 hr. onset, improved skin tone, longer duration) versus Botox ( 14 day onset, product floats around for 14 days, no skin tone improvement, short duration)
Once an injector switches to Daxi they too will never go back to Botox....Why would an injector sell a toxin which has no benefits for the patient and makes them less profit...Imagine, if Daxi had 60% market share, and Botox came on the market with their current cost to practices and benefits to the patient...NO ONE would switch to Botox!
Hopefully RVNC wakes up and realizes the PATIENT is the target market....
Injectors will ALWAYS make their profits and this in NOT RVNC's concern!!
IMHO - per discussions, MedSpas and Derms are adapting Daxi and moving away from Botox due to the added profit of Daxi vs Botox.
For every penny the average price of cosmetic Botox is decreased, it costs $2 million in therapeutic revenue per quarter to Abbive. A 5 cents reduction in the cosmetic price of Botox would result in an $40 million annual reduction in therapeutic revenues!
IMHO - you will see aesthetic practices come up with their our dilution of Daxi and priced accordingly. A practice could price Daxi equal to Botox but use a dilution of 1.5 units of Daxi to 1 units of Botox. Daxi will give the patient an additional 6 weeks of duration vs Botox and the practice makes more profit than Botox. Remember , Daxi onset is 24 hours versus Botox at 14 days. So with Daxi, a patient gets additional duration on both sides. Both the patient and the practice wins!
This will be a competitive advantage to the practitioner to offer all the additional benefits of Daxi ( 24 hr onset, improved skin tone, longer duration) at the same price. Patients will switch and once they use Daxi, they will never go back to Botox!
IMHO - Daxi sales have increased do to the price decrease! RVNC top sales reps hit Q3 plan numbers Monday/Tuesday and the remaining reps are hitting or getting very close to plan yesterday and today…remember, the sales rep plan numbers are always greater than the street forecast numbers.
I hope Foley provides an estimate of the quarterly sales numbers in the next 2 weeks to stop the bleeding!
It is time for the shorts to exit! The price adjustment is increasing sales!
IMHO - the RVNC sales reps and sales managers have been telling Foley and Dustin that the price of Daxi was too high for the last 4 months.
The upper management team did NOT listen and sales reps and managers who were actually afraid they would be fired by Dustin for giving them honest feedback! EGO is why this fumble happened !!!
I can not believe the RVNC Board of Directors allows this to happen…what an EGO driven management team!
Daxi needs to get into the hands of every injector so PATIENTS demand the product!
Have you seen Allergan telling injectors that their management team will ensure maximum profit for the injectors? Never, Allergan goes directly to the patient…Allergan puts the patient first and leaves it up to the injectors to determine their profit!
RVNC needs to wake up!!!! Patients are your target audience!!!
Give Patients a better mouse trap ( 24 hour onset, longer duration, improved skin tone) at a lower price ( lower than Botox) and sales just happen!!!
At some point, Daxi Double will be priced to the patient equal to Botox because they have the same profit margin!!!! 2 units of Daxi cost $5.50 and 1 unit of Botox costs $5.50..which toxin product will the patient pick??? Same cost to the patient..one lasts 5 plus months and one last 2 to 3 months.
RVNC needs to create this match up and start taking market share! RVNC can always raise prices after they have market share..and I guarantee every other toxin company will raise their toxin price!
Any practitioner who is saying they need 1.5 to 2 units of Daxi to equal 1 unit of Botox is lying to you.
The Daxi clinical trail was over 3,000 patients versus the Botox trial which was 300 patients. If anything, Botox is deceiving because it takes 7 to 14 days to take effect and only last an additional 2 1/2 months. Botox duration is really 2 1/2 months from the time it takes effect. Daxi takes effect in 24 hours and Daxi short last an additional 3 to 3 1/2 months and Daxi double lasts twice as long as Botox.
Who are these practitioners?